Alnylam Pharmaceuticals
ALNY
$249.99
+0.53%
Alnylam Pharmaceuticals is a commercial-stage biotechnology company and the pioneer of RNA interference (RNAi) therapeutics, with a marketed portfolio that includes Amvuttra and Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, and Oxlumo for primary hyperoxaluria type 1, plus partner-led programs such as Novartis' Leqvio and Sanofi's Qfitlia. As the only company with a broad, wholly owned RNAi commercial platform, Alnylam occupies a differentiated position as both a platform technology leader and a rare-disease franchise builder, now pushing its GalNAc conjugate technology into large cardio-metabolic, neuroscience, and hematology markets. The current investor debate centers on whether the company's dramatic swing to profitability — Q1 2026 revenue nearly doubled year over year to $1.17 billion with net income of $206 million — represents a durable inflection or a peak driven by one-time dynamics, a question made more urgent by the stock's roughly 47% one-year decline and a violent single-day drop in late July 2026 that erased more than a quarter of its value. Bulls point to the RNAi platform's expansion into large indications and a consensus price target implying substantial upside, while bears highlight a still-elevated valuation, a leveraged balance sheet, and the volatility that has characterized the shares over the past year.…
ALNY
Alnylam Pharmaceuticals
$249.99
Related headlines
Investment Opinion: Should I buy ALNY Today?
Based on the synthesis of fundamental, valuation, and analyst data, the recommendation is a Hold with a bias toward accumulation on weakness. The core thesis is that Alnylam's RNAi platform and recent profitability inflection are compelling, but the stock's extreme volatility, leveraged balance sheet, and premium valuation warrant caution until there is clearer evidence of sustainable earnings power. The analyst consensus is 'buy' with an average target of $371.35, implying 49% upside, but the wide target range ($256-$536) reflects high uncertainty. For investors with a high risk tolerance and a long-term horizon, the stock offers significant potential, but near-term risks are elevated.
The supporting evidence for a Hold is balanced. On the positive side, revenue grew 96.4% YoY in Q1 2026 to $1,167.2 million, net income turned positive at $206.0 million (17.6% net margin), and gross margins are robust at 81.9%. The forward PE of 19.9x is attractive if the company meets its EPS estimate of $16.10, and the PS ratio of 14.0x is near historical lows. However, the debt-to-equity of 1.62x and lumpy free cash flow ($48.7 million in Q1 2026) are concerns, and the stock's 46.9% one-year decline and 28% single-day drop highlight the risks. The valuation premium relative to peers (EV/EBITDA of 81.9x) leaves little room for error.
The biggest risks that could invalidate the thesis include: 1) a slowdown in Amvuttra's ATTR-CM launch due to competition or reimbursement challenges, 2) a pipeline failure in a key indication, or 3) a deterioration in the balance sheet or cash flow. The rating would upgrade to Buy if the stock pulls back to the $200-$220 range (near the 52-week low) while fundamentals remain intact, or if forward EPS estimates are raised. It would downgrade to Sell if revenue growth decelerates below 30% YoY or if free cash flow turns persistently negative. Relative to its history, the stock is undervalued on a PS basis, but relative to peers, it is fairly valued to slightly overvalued given the growth premium. Overall, the risk/reward is balanced, favoring a Hold with a long-term positive bias.
Sign up to view all
ALNY 12-Month Price Forecast
Alnylam presents a compelling growth story with a differentiated RNAi platform and a recent profitability inflection, but the stock's extreme volatility, leveraged balance sheet, and premium valuation warrant a neutral stance. The forward PE of 19.9x is attractive if the company meets its EPS estimate of $16.10, but the wide analyst target range and recent 47% one-year decline highlight significant uncertainty. The base case (50% probability) assumes steady execution and a target range of $340-$400, while the bear case (20%) risks a retest of the 52-week low. I would upgrade to bullish if Amvuttra's ATTR-CM launch shows sustained acceleration and free cash flow turns consistently positive; I would downgrade to bearish if revenue growth decelerates below 30% or a pipeline failure occurs.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alnylam Pharmaceuticals's 12-month outlook, with a consensus price target around $371.35 and implied upside of +48.5% versus the current price.
Average Target
$371.35
0 analysts
Implied Upside
+48.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$256 - $536
Analyst target range
Coverage is robust, with 26 analysts following the stock and a consensus recommendation of "buy" (mean rating of 1.69 on a 1-5 scale where 1 is Strong Buy). The average price target of $371.35 implies roughly 49% upside from the current price of $248.68, a strikingly bullish consensus for a stock that has fallen 46.9% over the past year. The consensus clearly leans bullish, and the magnitude of the implied upside suggests analysts view the July 2026 selloff as a significant overreaction rather than a fundamental deterioration — a view reinforced by the fact that the most recent institutional actions (B of A, Truist, and HC Wainwright in mid-July 2026) were all reiterations of Buy ratings rather than downgrades.
The target range is exceptionally wide, from a low of $256.00 to a high of $536.00 — a spread of $280, or more than the current share price itself. The low target of $256 implies just 3% upside and essentially prices in the stock staying at current levels, consistent with a view that margin compression, competitive pressure in ATTR-CM, or slower-than-expected pipeline progress caps the upside. The high target of $536 implies 116% upside and assumes aggressive multiple expansion alongside accelerating revenue growth and successful pipeline expansion into large cardio-metabolic and neuroscience markets. This enormous dispersion signals very high uncertainty and low conviction on the magnitude of the opportunity, even though the direction (bullish) is broadly agreed. The consensus EPS estimate of $16.10 for the forward period, with a range of $14.05 to $18.64, is the linchpin: if Alnylam delivers anywhere near that number, the forward PE of 19.9x makes the stock look inexpensive; if it misses materially, the entire valuation framework collapses. Investors should treat the wide target spread as a signal to size positions conservatively and focus on the specific catalysts — ATTR-CM launch metrics and pipeline readouts — that will determine which end of the range the stock ultimately reaches.
Drowning in data?
Find the real signal!
Bulls vs Bears: ALNY Investment Factors
The bull case rests on Alnylam's explosive revenue growth, swing to profitability, and a differentiated RNAi platform that is expanding into large markets, supported by a consensus price target implying 49% upside. The bear case highlights the stock's severe volatility, leveraged balance sheet, premium valuation, and technical weakness, with a 47% one-year decline and a 28% single-day crash underscoring the risks. Currently, the bear evidence appears stronger due to the recent price action and balance sheet concerns, but the fundamental inflection is undeniable. The most critical tension is whether the Q1 2026 profitability is sustainable or a peak; if earnings continue to scale, the forward PE of 19.9x could prove conservative, but any stumble could validate the bears and lead to further downside. Resolution of this debate will likely hinge on the ATTR-CM launch trajectory and pipeline readouts over the next 12 months.
Bullish
- Revenue nearly doubled YoY: Q1 2026 revenue reached $1,167.2 million, up 96.4% from $594.2 million in Q1 2025, driven by Amvuttra's expansion into ATTR-CM and a diversified product mix. This growth rate is exceptional for a commercial-stage biotech and suggests the RNAi platform is hitting an inflection point.
- Sustained profitability with high margins: Net income of $206.0 million in Q1 2026 marks the third consecutive profitable quarter, with a net margin of 17.6% and gross margin of 81.9%. Operating leverage is evident as operating margin expanded to 23.0% from 3.0% a year earlier.
- Analyst consensus implies 49% upside: 26 analysts rate the stock a 'buy' with an average target of $371.35, implying 49% upside from $248.68. The high target of $536 suggests significant optionality from pipeline success in large markets like cardio-metabolic and neuroscience.
- Attractive forward valuation: Forward PE of 19.9x is reasonable for a company growing revenue at 96% YoY, especially compared to the trailing PE of 166x. The PS ratio of 14.0x is near the low end of its historical range (29.5x-92.5x), indicating potential undervaluation.
Bearish
- Extreme stock volatility and drawdown: The stock has fallen 46.9% over the past year and experienced a 28% single-day drop in late July 2026, with a max drawdown of -58.17%. This volatility, despite a low beta of 0.30, indicates high idiosyncratic risk and poor recent performance.
- Leveraged balance sheet and weak cash flow: Debt-to-equity is 1.62x with total debt to capitalization at 54.2%, and interest coverage is only 3.88x. Free cash flow is lumpy, with Q1 2026 FCF of just $48.7 million due to a $281.7 million working capital outflow.
- Premium valuation leaves no room for error: PS ratio of 14.0x and EV/EBITDA of 81.9x are well above sector norms, and the forward PE of 19.9x relies on EPS estimates of $16.10 that are more than 10x the trailing EPS. Any miss could trigger sharp multiple compression.
- Wide analyst target dispersion: The target range spans from $256 to $536, a $280 spread that exceeds the current share price. This signals low conviction on the magnitude of the opportunity and high uncertainty around pipeline and commercial outcomes.
ALNY Technical Analysis
Alnylam is in a pronounced downtrend that has only recently begun to stabilize. The stock is down 46.9% over the past year and 37.9% year-to-date, trading at $248.68 versus a 52-week high of $495.55 and a 52-week low of $197.81 — positioning it at roughly 17% of its 52-week range, deep in the lower quartile. That placement reflects a stock that has been in distribution for most of the year, though the fact that it sits about 26% above its 52-week low suggests the worst of the selling may have passed and a base is forming rather than a continued freefall. The most striking technical event is the late-July gap: the stock closed at $286.62 on July 29 and reopened at $205.48 on July 30, a roughly 28% single-session collapse that created a massive unfilled gap and reset the entire technical structure. Since that capitulation low, price has recovered from $205.48 to $248.68, a gain of about 21%, but remains far below the pre-gap level, leaving a heavy band of overhead supply between $270 and $290.
Short-term momentum has turned decisively positive even as the longer-term trend remains negative, creating a classic divergence. The stock is up 11.04% over the past month versus a 1.06% decline in SPY, producing relative strength of +12.10 percentage points, while the three-month change is still -12.08% and the six-month change is -20.65%. This means the one-month rally is a genuine counter-trend bounce off deeply oversold conditions rather than confirmation of a new uptrend, and the 3-month relative strength of -15.12 confirms the stock has lagged the market badly over any window longer than a month. Volume of roughly 1.18 million shares on the latest session is unremarkable, and with a short ratio of 3.21 days-to-cover, short positioning is moderate rather than extreme — not enough to fuel a violent squeeze, but enough to add upside fuel if the recovery continues. The key question is whether the September push through $267 (September 2 close of $267.40) marks the start of a higher-low structure or simply the upper bound of a volatile trading range.
Key technical levels are unusually well defined given the gap event. Immediate resistance sits at the $267-$270 area, where the early-September rally stalled, followed by the $286-$290 zone that capped the stock before the July collapse; a decisive break above $290 would signal that the market has fully absorbed the July shock and would open the door to a retest of the $320-$330 region. Support is anchored at the $197.81 52-week low, with the $205-$220 post-gap base serving as the first line of defense — a breakdown below $197.81 would confirm the downtrend and likely trigger momentum-driven selling. The beta of 0.30 is a critical and counterintuitive data point: despite the stock's enormous realized volatility (max drawdown of -58.17%), its low beta to the market means the wild swings are driven by company-specific and sector-specific catalysts rather than broad market moves, so index-level hedges provide little protection and position sizing must account for idiosyncratic gap risk. The combination of a 0.30 beta, a -58.17% max drawdown, and a 28% single-day gap is a textbook profile of a binary, event-driven biotech where technical levels matter less than clinical and commercial catalysts.
Beta
0.30
0.30x market volatility
Max Drawdown
-58.2%
Largest decline past year
52-Week Range
$198-$496
Price range past year
Annual Return
-46.3%
Cumulative gain past year
| Period | ALNY Return | S&P 500 |
|---|---|---|
| 1m | +9.3% | -2.0% |
| 3m | -11.3% | +1.4% |
| 6m | -20.6% | +15.0% |
| 1y | -46.3% | +15.7% |
| ytd | -37.5% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALNY Fundamental Analysis
Alnylam's revenue trajectory has inflected sharply upward. Q1 2026 revenue reached $1,167.2 million, up 96.4% year over year from $594.2 million in Q1 2025, and up sequentially from $1,097.0 million in Q4 2025 and $1,249.0 million in Q3 2025. The multi-quarter trend shows a business that has roughly doubled its top line in a year, with the product segment contributing $1,036.1 million of the Q1 total, GIVLAARI adding $74.4 million, and ONPATTRO contributing $20.5 million — a mix that shows the franchise is no longer dependent on the legacy Onpattro asset. The sequential dip from Q3 2025's $1,249.0 million to Q4's $1,097.0 million and Q1 2026's $1,167.2 million warrants monitoring, but the year-over-year doubling is the dominant signal and supports the thesis that Amvuttra's expansion into ATTR-CM is a genuine growth driver rather than a one-time bolus.
Profitability has swung from deeply negative to solidly positive in a remarkably short period. Q1 2026 net income was $206.0 million (net margin of 17.6%) on a gross margin of 81.9%, compared with a net loss of $57.5 million in Q1 2025 and a loss of $66.3 million in Q2 2025. The quarterly progression — from -$57.5M to -$66.3M to +$251.1M to +$186.4M to +$206.0M — shows the crossover to sustained profitability occurred in Q3 2025 and has held for three consecutive quarters. Gross margin has been stable in the 76%-84% band across the last five quarters, which is consistent with a premium rare-disease biologics franchise, and operating margin of 23.0% in Q1 2026 (versus 3.0% in Q1 2025) demonstrates meaningful operating leverage as revenue scales against a relatively fixed R&D base of $364.9 million. The one caveat is that Q1 2026 benefited from a -$15.7 million income tax benefit and $26.6 million of interest income, so pre-tax profitability of $221.7 million is the cleaner read on core earnings power.
Balance sheet and cash flow metrics are the weakest part of the fundamental picture. Debt-to-equity stands at 1.62x with total debt to capitalization of 54.2%, and the current ratio of 2.76 and quick ratio of 3.06 provide ample near-term liquidity, supported by $1.71 billion of cash at the end of Q1 2026. However, free cash flow is lumpy and modest relative to the market cap: TTM free cash flow is $641.3 million, but quarterly FCF has swung from -$127.3 million in Q1 2025 to +$313.0 million in Q3 2025 to +$48.7 million in Q1 2026, and the Q1 2026 figure was dragged down by a $281.7 million working capital outflow driven largely by a $176.0 million payables drawdown and $110.4 million receivables build. ROE of 39.8% and ROA of 12.3% look strong but are flattered by the leveraged capital structure and the recent profitability inflection; interest coverage of 3.88x is adequate but not comfortable, and the company remains dependent on continued revenue execution to service its debt. The cash flow statement shows no buybacks and no dividends, with capital expenditure running at only $21.8 million in Q1 2026 — a capital-light model that means incremental revenue drops through to cash efficiently once working capital normalizes.
Quarterly Revenue
$1.2B
2026-03
Revenue YoY Growth
+96.4%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$641338000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALNY Overvalued?
Because Alnylam generated positive trailing net income (EPS of $0.006 on a trailing basis, with Q1 2026 net income of $206.0 million), the PE ratio is the appropriate primary metric, though the trailing figure is distorted by the loss-making quarters still in the trailing window. The trailing PE of 166.4x is nearly meaningless as a valuation signal, but the forward PE of 19.9x is the more informative number and implies the market expects earnings to roughly octuple from trailing levels. That enormous gap between trailing and forward PE — a factor of more than eight — tells you the market is pricing in a full-year 2026-2027 earnings ramp consistent with the consensus EPS estimate of $16.10, which itself is a dramatic step-up from the $1.55 reported in Q1 2026 alone. The credibility of that forward estimate is the single most important variable in the valuation case.
Relative to the biotechnology sector, Alnylam trades at a significant premium on most metrics. Its PS ratio of 14.0x and EV/Sales of 6.8x sit well above typical large-cap biotech levels, and the PB ratio of 66.0x is extreme, reflecting a relatively thin book value against a $52.1 billion market cap. The EV/EBITDA of 81.9x is also far above the sector norm, though this metric is distorted by the recent profitability inflection and should compress rapidly if forward estimates are met. The premium is defensible on the basis of Alnylam's 96.4% revenue growth, 81.9% gross margin, and unique RNAi platform, but it leaves little margin for error — any disappointment on the ATTR-CM launch or pipeline readouts would likely compress multiples sharply, as the July 2026 drawdown demonstrated.
Historically, Alnylam's valuation has been extremely volatile because the company only recently crossed into profitability. The PS ratio has ranged from roughly 29.5x (Q3 2023) to 92.5x (Q3 2022) and now sits at 14.0x — near the low end of its multi-year band, which is a meaningful signal that the market has de-rated the stock even as fundamentals improved. The PE ratio history is unusable for comparison because the company was loss-making for most of the period, but the current forward PE of 19.9x against a historical PS range that once exceeded 90x suggests the stock is now valued more like a mature pharma franchise than a speculative platform story. That re-rating could represent a genuine value opportunity if growth persists, or it could reflect the market's skepticism that the current earnings level is sustainable — the resolution of that debate will drive the stock's next major move.
PE
166.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 38x~71x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
81.9x
Enterprise Value Multiple
Investment Risk Disclosure
Alnylam's financial risks are significant, primarily stemming from its leveraged balance sheet and uneven cash flow. With a debt-to-equity ratio of 1.62x and total debt to capitalization of 54.2%, the company carries substantial debt relative to its equity, and interest coverage of 3.88x is only adequate. Free cash flow is volatile, swinging from -$127.3 million in Q1 2025 to +$313.0 million in Q3 2025 and back to +$48.7 million in Q1 2026, largely due to working capital fluctuations. Additionally, the company's profitability is recent and may not be durable; Q1 2026 net income of $206.0 million benefited from a $15.7 million tax benefit and $26.6 million interest income, and pre-tax income of $221.7 million is the cleaner measure. If revenue growth decelerates or expenses rise, the company could quickly return to losses, especially given its high operating expenses (R&D of $364.9 million in Q1 2026).
Market and competitive risks are pronounced, given the stock's extreme volatility and premium valuation. Despite a beta of 0.30, the stock has a max drawdown of -58.17% and experienced a 28% single-day drop in July 2026, indicating that idiosyncratic risks dominate. The valuation is rich: PS ratio of 14.0x and EV/EBITDA of 81.9x are well above typical biotech levels, leaving little margin for error. Competition in ATTR-CM is intensifying, with potential entrants like BridgeBio's acoramidis and others, which could pressure Amvuttra's market share and pricing. Regulatory and clinical trial risks are ever-present in biotech; any safety signal or efficacy miss in the pipeline could devastate the stock, as seen in the July crash. Macro sensitivity is lower due to the low beta, but sector rotation away from high-growth biotech could still weigh on the shares.
The worst-case scenario for Alnylam involves a combination of commercial disappointment and pipeline failure. If Amvuttra's ATTR-CM launch stalls due to competition or reimbursement hurdles, and a key pipeline readout (e.g., in cardio-metabolic or neuroscience) fails, revenue growth could decelerate sharply, causing the forward EPS estimate of $16.10 to be revised down. This would likely trigger a re-rating to a lower multiple, pushing the stock toward its 52-week low of $197.81 or the analyst low target of $256. From the current price of $248.68, a drop to $197.81 represents a 20.5% decline, but in a more severe scenario, the stock could retest its max drawdown level, implying a potential loss of over 50% from the 52-week high. Investors should be prepared for significant downside if the growth narrative breaks.
FAQ
The key risks for ALNY are ranked as follows: 1) Financial risk: high debt-to-equity of 1.62x and volatile free cash flow, with Q1 2026 FCF of only $48.7 million due to a $281.7 million working capital outflow. 2) Competitive risk: intensifying competition in ATTR-CM from BridgeBio's acoramidis and other therapies could pressure Amvuttra's market share and pricing. 3) Pipeline risk: any failure in the company's broad pipeline, especially in large indications like cardio-metabolic or neuroscience, could severely impact the growth narrative. 4) Valuation risk: the stock trades at a premium (EV/EBITDA of 81.9x), leaving little room for error; a miss on earnings could trigger a sharp sell-off. Additionally, the stock's extreme volatility (max drawdown of -58.17%) and low beta of 0.30 mean that idiosyncratic risks dominate, and investors should be prepared for significant swings.
Our 12-month forecast for ALNY includes three scenarios. The base case (50% probability) targets $340-$400, assuming steady execution and revenue growth of 40-50% in 2027, with the stock trading near the analyst average target of $371.35. The bull case (30% probability) targets $450-$536, driven by successful ATTR-CM launch and positive pipeline readouts, approaching the analyst high target. The bear case (20% probability) targets $197-$256, assuming competitive pressures and pipeline setbacks lead to decelerating growth and multiple compression. The most likely scenario is the base case, hinging on Amvuttra's commercial trajectory and the company's ability to meet its EPS estimate of $16.10. Key catalysts include quarterly earnings, pipeline data, and competitive developments.
ALNY's valuation is nuanced. On a trailing basis, the PE of 166x and PS of 14.0x appear elevated, but these are distorted by the recent profitability inflection. The forward PE of 19.9x is more reasonable, assuming the company meets its consensus EPS estimate of $16.10, which implies a massive earnings ramp. Relative to its own history, the PS ratio of 14.0x is near the low end of its multi-year range (29.5x-92.5x), suggesting the stock has been de-rated. However, compared to the broader biotech sector, the EV/EBITDA of 81.9x and PB of 66x are premium multiples. The market is pricing in significant growth, so any disappointment could lead to multiple compression. Overall, the stock appears fairly valued to slightly undervalued if growth targets are met, but overvalued if they are not.
Whether ALNY is a good buy depends on your risk tolerance and time horizon. The stock has fallen 46.9% over the past year and trades at $248.68, but analysts see 49% upside to their average target of $371.35. The company's Q1 2026 revenue grew 96.4% YoY to $1.17 billion, and it reported net income of $206 million, marking a profitability inflection. However, the balance sheet is leveraged (debt-to-equity of 1.62x) and free cash flow is lumpy, while the stock's 28% single-day drop in July 2026 highlights extreme volatility. For long-term investors comfortable with biotech risk, the growth potential in RNAi therapeutics could be rewarding, but position sizing should be conservative. A better entry point might be near the 52-week low of $197.81 or upon clearer evidence of sustainable cash flow.
ALNY is more suitable for long-term investment than short-term trading, given its binary, event-driven nature and high volatility. The stock has a beta of 0.30, but its max drawdown of -58.17% and 28% single-day gap illustrate extreme idiosyncratic risk, making short-term trading highly speculative. The company pays no dividend, so returns depend entirely on capital appreciation. For long-term investors, the RNAi platform's potential in large markets and the recent profitability inflection offer a compelling growth story, but patience is required as pipeline readouts and commercial execution play out over years. A minimum holding period of 3-5 years is advisable to ride out volatility and allow the pipeline to mature. Short-term traders should be aware of the wide analyst target range and technical resistance levels.
